Results 231 to 240 of about 174,356 (352)

BRAF Inhibitors and Control of Mutant BRAF Effects

Cancer Therapy & Oncology International Journal, 2023
openaire   +1 more source

Clinical Outcomes of Dacarbazine After Failure of Immune Checkpoint Inhibitors: A Case Study of 15 Japanese Patients With Malignant Melanoma

The Journal of Dermatology, EarlyView.
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

A novel murine model for sporadic, malignant peripheral nerve sheath tumors, driven by BrafV600E and Pten loss

Disease Models & Mechanisms
Julien Debbache, Myriam Gwerder, Elisabeth Rushing, Lukas Sommer   +3 more
doaj   +1 more source

Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. [PDF]

NPJ Precis Oncol
Pu T, Peddle AM, Wirapati P, Tsantoulis P, Wu Q, Hong Y, Samuel L, Desai J, Riener M, Saridaki Z, Cunningham D, Tejpar S.   +11 more
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer [PDF]

, 2019
Baranski, Thomas, DeWees, Todd, Grigsby, Perry, Henke, Lauren, Lin, Alexander J, Markovina, Stephanie, Pfeifer, John, Samson, Pamela, Schwarz, Julie   +8 more
core   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Langerhans cell histiocytosis manifesting at birth: a neonatal case with BRAF V600E mutation. [PDF]

Diagn Pathol
Tang W, Wang P.
europepmc   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

Targeting BRAF in cancers - from molecular diagnostics to personalized therapy. [PDF]

BioTechnologia (Pozn)
Pyc Z, Rygiel R, Michalowska D, Ekiert M, Laczmanska I.   +4 more
europepmc   +1 more source